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Building upon the concept of schedule-specific biochemical modulation of 5-fluorouracil (FU), which alternates bolus and continuous
infusion (CI) FU, we have incorporated oxaliplatin (l-OHP) following the bolus part of the regimen to explore the activity of this new
combination. Patients with advanced, untreated, measurable colorectal cancer received sequential methotrexate (MTX) (days 1 and
15)-l-OHPþFU (days 2 and 16) (200, 85 and 600mgm
 2, respectively) followed by 3 weeks of CI FU (200mgm
 2day
 1) given
from day 29 to 50, modulated by weekly leucovorin (LV) (20mgm
 2). After 1 week of rest, the second cycle was started. The
treatment was continued until progression or patient’s refusal. According to the intention-to-treat analysis on all 46 patients accrued,
the response rate was 42% (95% CL¼28–55%), with three complete responses and 16 partial responses. The median overall
survival was 15.9 months and the median progression-free survival 6.9 months. Toxicity was very mild, with the bolus part of the
regimen more toxic than the infusional part (24 vs 7% of grade III–IV, respectively). This new combination of MTX-l-OHP FU
followed by FU CI is well tolerated, feasible and produces activity results similar to other more simple, but more toxic, regimens. Pros
and cons of the different fluoropyrimidines–l-OHP combinations are discussed.
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Chemotherapy, both first and second and possibly third line,
prolongs survival as compared to best supportive care in the
treatment of advanced colorectal cancer (Cunningham and
Glimelius, 1999; Jonker et al, 2000; Baldwin, 2002). Doublets
(either 5-fluorouracil (FU)þirinotecan or FUþoxaliplatin (l-
OHP)) prolong survival in first and second line as compared to
modulated bolus FU (de Gramont et al, 2000; Douillard et al, 2000;
Levi et al, 2001; Baldwin, 2002; Saltz et al, 2000) and it has recently
emerged that giving ‘doublets’ means using infusional FU with
either irinotecan or l-OHP; otherwise, these combinations are too
toxic (Grothey et al, 2002; Ravaioli et al, 2002; Saltz et al, 2000;
Goldberg et al, 2003). Doublets are more efficacious but more toxic
than FU alone, so it is uncertain whether it is better to start with a
doublet or to use the drugs sequentially; in addition, doublets are
more efficacious than FU alone only in patients under age 70, with
a good performance status (PS) and relatively normal serum
chemistries (Knight et al, 2000). The scenario of advanced
colorectal cancer treatment is completed by the oral fluoropyr-
imidines, which may be a valid alternative to FU because they are
substantially equivalent to bolus FU but are preferred by patients
(Liu et al, 1997; Borner et al, 2000; Cassidy et al, 2002), and by
targeted therapies, promising, but still highly experimental (Saltz
et al, 2001; Cunningham et al, 2002; Giantonio et al, 2002; King
et al, 2002).
We have published four clinical trials based upon our
hypothesis that FU is indeed two different drugs depending upon
the schedule of administration (Sobrero et al, 1993, 1995, 2000,
2001; Aschele et al, 1998): maximal enhancement of bolus FU is
more likely obtained with drugs that enhance the RNA effect of the
fluoropyrimidine such as methotrexate (MTX), while leucovorin
(LV), which selectively enhances the TS* inhibitory activity of FU,
may result in greater potentiation when the fluoropyrimidine is
administered as continuous infusion (CI) (Aschele et al, 1998). We
are now in the process of integrating the new agents irinotecan and
l-OHP in our basic regimen. In particular, we added l-OHP to
MTX-FU bolus, leaving the infusional part unchanged. Pre-
clinical data on four human colorectal cancer cell lines suggest that
l-OHP synergises more with short-term exposure to FU than with
prolonged FU exposures (Fischel et al, 1998). In addition, our
previous experience with this regimen without l-OHP (Sobrero
et al, 1995) indicated that the toxicity of the MTX-FU part was
much lower than that of the CI FU part. For this reason, we
decided to add l-OHP to the first part of the regimen. Preliminary
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lto this study, we explored the feasibility of administering full-dose
l-OHP 130mgm
 2, but observed prohibitive toxicity; therefore, we
chose 85mgm
 2 of the diaminocyclohexane (DACH) platinum
compound.
PATIENTS AND METHODS
Eligibility criteria
Patients enrolled in the study had histologically confirmed,
unresectable metastatic colorectal cancer and bidimensionally
measurable disease. No prior chemotherapy for metastatic disease
was allowed, while adjuvant chemotherapy was permitted if
completed at least 6 months before study entry. Radiation therapy
was allowed as long as it did not encompass the indicator lesions.
All patients had an ECOG PS p2. Adequate bone marrow, liver
and renal functions were required.
Additional eligibility criteria included geographic accessibility,
the absence of clinically relevant ascites and the absence of other
medical conditions clearly contraindicating the delivery of any
chemotherapy.
Informed consent was required. Before treatment, patients were
informed as to (a) the presence of metastatic colorectal cancer, (b)
the poor prognosis of their disease and (c) the experimental nature
of this treatment protocol. Upon study entry, all patients were
given a schedule of drug treatment along with written information
about the anticipated toxicities.
Treatment plan
The regimen consisted of the alternating regimen of bolus and
infusional FU that we previously tested in a phase II trial and that
was derived from two well-studied regimens: sequential MTX and
bolus FU (Marsh et al, 1991) and CI FU modulated by LV
(Leichman et al, 1993). Oxaliplatin was added to the bolus part.
One complete cycle of treatment consisted of two MTX-l-
OHP FU bolus treatments (200mgm
 2-85mgm
 2 given i.v. as
a 2-h infusion in 500ml of 5% D-glucose (D5W) followed by
600mgm
 2, respectively) given on days 1, 2 and 15, 16 along with
LV rescue (15mg) given p.o. q 6h  6 doses, followed by 3 weeks
of CI FU (200mgm
 2) given from day 29 to 50, modulated by
weekly LV (20mgm
 2). After 1 week of rest, the second cycle was
started on day 57, provided that the patient had recovered from
toxicity. The entire duration of the cycle is thus 8 weeks (Figure 1).
Through implanted catheters and a venous Port-a-cath (Pharma-
cia) connected to a portable programmable external pump (CADD-
1, Pharmacia) or disposable elastomeres (Baxter) CI FU was
administered. The infusional cassettes or elastomeres were
changed weekly if no toxicity developed earlier.
Toxicity was evaluated on days 1, 15, 29, 36, 43, 50 and 57.
Complete blood counts were obtained on the same days. Liver
function tests, blood urea nitrogen, creatinine and electrolytes
were obtained monthly.
Dose modification criteria for the MTX-l-OHP FU regimen
were as follows: no dose reduction for gastrointestinal grade I and
II toxicity. For grade III diarrhoea or mucositis, the treatment was
delayed until recovery and the doses of MTX, l-OHP and FU of the
next cycle were decreased by 50%. The dose was reduced, after
recovery, by 50% also for WBC o3000mm
3 or platelets
o75000mm
3 on the day of recycle. Treatment was discontinued
in case of grade IV toxicity.
Upon the first signs of mucositis and/or palmar-plantar
dysaesthesia/burning, CI FU was discontinued and resumed when
these symptoms abated. In the case of severe (grade III) mucositis,
the infusion was resumed at a reduced FU dose (50%). The dose of
LV during the infusional treatment was not modified in this study.
Toxicity is expressed according to WHO criteria (Miller et al,
1981).
Response evaluation
Patients who received at least 2 months of therapy (one cycle), with
adequate pretreatment and follow-up radiographic studies, were
considered assessable for response, as were patients who
experienced rapid disease progression after at least two courses
of bolus FU.
Measurable tumour was defined as a tumour mass that could be
clearly measured in two dimensions by adequate imaging
techniques and response evaluation was according to the WHO
criteria (Miller et al, 1981). Indicator lesions were measured at
each successive cycle. The baseline tumour areas and their
variations at each successive evaluation were expressed in cm
2.
Progression-free survival (PFS) and overall survival (OS) were
measured from the date of registration to the date of disease
progression as defined above or to the date of death, respectively
and calculated using the Kaplan–Meier method (Kaplan and
Meier, 1958). Early progressions and deaths, toxic deaths if any,
early withdrawals and deaths from other causes were included as
failures.
Statistical methods
The general philosophy behind this phase II study was that l-OHP
should add some further activity to our alternating bolus-
infusional modulated FU regimen. The new combination would
be regarded as promising if an additional 15% response rate is
added to our basic regimen. Since our standard alternating
regimen without l-OHP affords 30–35% response rate, we were
searching for a range of activity around 40–60% to consider the
new combination for a new phase III study.
According to the two-stage Simon’s design (Simon, 1989),
setting Po¼40 and P1¼60%, with an alpha error¼0.1 (reflecting
the chances to accept an ‘inactive’ regimen) and a beta error¼0.1
(reflecting the chances of accepting as ‘active’ a truly inactive
regimen), the treatment will be discontinued if less than seven
responses are observed among the first 18 patients. Otherwise, we
will proceed to the second stage, where 22 responses over 46
patients will be necessary to define the study as successful and
proceed further with the clinical development of this combination.
RESULTS
Patient characteristics
Between December 1998 and January 2001, 46 patients meeting the
eligibility criteria were registered from six participating Institu-
tions. Table 1 shows patient characteristics. In all, 91% of patients
had had surgery on the primary neoplasm. A total of 13% of
patients had received prior adjuvant chemotherapy consisting in
   l-OHP  l-OHP 
24 h ↓   24 h    ↓
MTX-------->     FU    • MTX-------->    FU      • CI FU  + wkly LV
   LV  LV  
d 1       d 2    d 15 d 16  d 29   d 50 
Figure 1 Design of drug regimen. One cycle¼8 weeks. In the first part
of the regimen, patients were given MTX 200mgm
 2 i.v. diluted in 500ml
of D5W, infused in 1h, days 1 and 15; oxaliplatin 85mgm
 2 given i.v. as a
2-h infusion in 500ml of D5W followed by FU 600mgm
 2 i.v. bolus, days 2
and 16 along with LV rescue (15mg) given p.o. q 6h  6 doses. In the
second part of the cycle, patients were given FU 200mgm
 2day
 1 CI  3
weeks (from day 29 to 50), modulated by weekly LV (20mgm
 2 i.v. bolus).
After 1 week of rest, the second cycle was started on day 57.
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lsix cycles of FUþLV. Lesions were measured by CT scan in 34
patients, the remaining being measured by NMR. The median
measured baseline tumour area was 21cm
2 (range 1–343).
Treatment outcome
Five patients were not evaluable for response. This was due to
rapid clinical deterioration in one patient not allowing completion
of the first cycle of treatment; four patients refused to continue
treatment after the first drug administration due to toxicity.
According to the intention-to-treat principle, all these patients
were included in the analysis of response as failures.
Three complete (CR) and 16 partial (PR) responses were
obtained (response rate, 42% on the intention-to-treat basis; 95%
confidence limits¼28–55); in addition, 30% of patients had stable
disease (Table 2). A total of 13 failures were reported: eight
patients progressed after the first cycle of treatment and four
patients refused to continue treatment. In all, 90% of the cases of
progression were due to the appearance of new lesions rather than
enlargement of the indicator lesions.
The median time to achieve a PR or CR was 91 days (range 57–
186), with initial responses attained after one cycle (12 cases), two
cycles (four cases) and three cycles (three cases). Two out of three
CR were observed after two cycles.
None of the patients in this study underwent surgical explora-
tion in order to resect residual disease.
Only five of the 19 responses were obtained in patients with
multiple metastatic sites, the rest being liver only (11 patients),
lung only (one patient) and extra hepatic intra-abdominal disease
(two patients).
The combined CR and PR rate was 46 and 31% in patients with
an ECOG PS of 0 and 1, respectively.
Age and sex did not appear to influence the overall clinical
response.
The median duration of response was 5 months (range 2–18)
and the median duration of stable disease was 3 months (range
2–7). All patients are now off treatment.
Two patients declined further chemotherapy while they were
still responding; they were considered treatment failures as of the
date the treatment was discontinued. After a median follow-up
time of 21 months, all patients have progressed and 16 patients are
still alive. The median PFS was 6.9 months (Figure 2) with an OS of
15.9 months (Figure 3).
Safety
A total of 112 cycles of treatment (2 months each) were
administered, with a median of two cycles (range 0–4) per patient.
Table 3 reports the worst toxicity of each type, suffered by each
patient, across all cycles. The two parts of the regimen are
considered separately. No toxic deaths were reported following
either part of the regimen.
Mucositis was the most common severe side effect: 11% of
patients in the bolus part and 2% in the CI part experienced grade
III–IV. Nausea and vomiting were the most frequent side effects in
both parts: 9% of patients experienced grade III nausea and
vomiting, while no grade III was reported in the CI part.
A total of 53% of patients experienced grade I or II neurotoxicity
after l-OHP administration. In most cases, this side effect was
limited to the 2–3 days after chemotherapy and recovered between
cycles. No grade III or IV was reported.
Table 1 Baseline patient characteristics
N 46
Median age (range) 63 (40–78)
Male, n (%) 31 (67)
Female, n (%) 15 (33)
ECOG PS, n (%)
0 30 (65)
1 16 (35)
Primary tumour site, n (%)
Colon 38 (83)
Rectum 8 (17)
Number of organs involved, n (%)
1 26 (57)
2 18 (39)
X3 2 (4)
Site of metastases, n (%)
Liver 27 (59)
Lung 5 (11)
Peritoneum/nodes/others 14 (30)
Prior adjuvant chemotherapy, n (%) 13 (28)
Median number of lesions measured per patient (range) 3 (1–7)
Median baseline tumour area (cm
2) (range) 21 (1–343)
Table 2 Response to treatment: intention-to-treat analysis (n¼46)
Complete responses 3 (7 %)
Partial responses 16 (35%)
Stable disease 14 (30%)
Failures 13 (28%)
Response rate (95% CL) 42% (28–55)
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Figure 2 Kaplan–Meier PFS curve for all 46 patients.
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Figure 3 Kaplan–Meier survival curve for all 46 patients.
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lHand–foot syndrome was almost exclusive of the CI part with
an incidence of 30% of grade I and 4% of grade II.
No major catheter-related complications have been reported in
this series of patients coming from centres with long-standing
experience in protracted infusion of FU.
DISCUSSION
Our study shows that high activity can be obtained at the cost of
low toxicity using this original but complicated schedule of four
drugs.
This study is original under two aspects: first, it is the logic
extension of our series of studies on schedule-selective biochem-
ical modulation as mentioned in the introduction (Sobrero et al,
1993, 1995, 2000, 2001; Aschele et al, 1998); second, it shows the
feasibility of combining sequential MTX-FU with l-OHP. The
question we are focusing on now is where to place this regimen in
the scenario of advanced colorectal cancer treatment with
fluoropyrimidines–l-OHP combinations. Table 4 reports the main
features of these regimens in phase II and III studies on advanced
colorectal cancer. Four fluoropyrimidine schedules have been
combined with the DACH compound: daily bolus  5 (Ravaioli
et al, 2002), weekly bolus (Hochster et al, 2003), infusional FU (de
Gramont et al, 2000; Grothey et al, 2002; Andre ´ et al, 2003;
Goldberg et al, 2003) and the oral route using capecitabine or UFT
(Bennouna et al, 2003; Grothey et al, 2003; Van Cutsem et al,
2003). Oxaliplatin has either been used at 50 q 1, 85 q 2 or 130 q 3
or 4 weeks with a calculated planned dose intensity of
approximately 40–45mgm
 2week
 1 in all these studies except
FOLFOX7, which is intended to deliver 50% higher dose intensity.
Very satisfactory response rates have been reported in all these
trials (range 32–64%) and considering that the number of patients
accrued in each trial is high (range 42–313, median 118), the 95%
CI on these values is narrow. Under these conditions, toxicity and
convenience play a major role in the selection of the ‘best’ regimen.
While the incidence of mucositis was very low in all the reports,
diarrhoea was almost prohibitive with the bolus FU regimens and
very relevant with the oral fluoropyrimidine combinations,
whereas neutropenia was very common (40–50%) with the
classical FOLFOX4. The incidence of neurotoxicity is hard to
comment because it was dependent on the cumulative l-OHP dose
and this figure is not available in the great majority of the reports.
Our study employs half as much l-OHP per cycle: in fact the dose
intensity would be 42.5mgm
 2week
 1 during the month of
treatment with MTX-FUþl-OHP, but this figure is halved by
alternating with 1 month of infusional FU without l-OHP. It is thus
not surprising that our regimen is the only one without high-grade
neurotoxicity, making it a potential candidate for prolonged
chemotherapy programme. The whole spectrum of toxicity is also
particularly favourable with low values all across. One would thus
Table 3 Toxicity: worst WHO grade per patient across all cycles
(n¼46)
MTX-l-OHP FU
toxicity grade (%)
CI FU+6-S-LV toxicity
grade (%)
Toxicity I II III IV I II III IV
Mucositis 15 9 9 2 19 11 2 0
Diarrhoaea 13 4 7 0 11 6 2 0
Nausea/vomiting 32 11 9 0 28 9 0 0
Neurotoxicity 43 10 0 0 0 0 0 0
Conjunctivitis 15 0 0 0 17 2 0 0
Hand–foot syndrome 4 2 0 0 30 4 0 0
Haematological 28 9 0 4 28 19 6 0
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lbe tempted to further pursue this strategy into phase III. In
designing the study we set the Po value at 40% response rate. The
results are therefore just in the range of uncertainty whether to
bring this regimen to a phase III study or to drop it. On the one
hand, the very low toxicity is encouraging for further testing and
on the other hand, equiactive but more simple combination
regimens with oral fluoropyrimidines or infusional FU plus l-OHP
or irinotecan are available. This is particularly true considering the
relatively good prognostic factors of our patient population.
Consequently, our overall interpretation of these data is that they
are not good enough for further studies in the light of the
complexity of the regimen. Much more substantial improvement in
activity would be needed (P1 was in fact set at 60%, expecting a
PFS of approximately 10 months) before embarking onto a
randomised phase III trial. For this reason, we are now accruing
patients on a similar regimen incorporating both CPT-11 and l-
OHP.
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